Acumen Pharmaceuticals - ABOS Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings or view top-rated stocks.

3 analysts have issued 1 year target prices for Acumen Pharmaceuticals' stock. Their ABOS share price forecasts range from $15.00 to $22.00. On average, they expect the company's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price.
View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts.

Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of 2023. Since then, ABOS shares have decreased by 28.3% and is now trading at $3.87.
View the best growth stocks for 2023 here.

Acumen Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 634,100 shares, an increase of 6.2% from the February 13th total of 597,000 shares. Based on an average trading volume of 81,300 shares, the short-interest ratio is currently 7.8 days. Approximately 2.3% of the shares of the stock are short sold.
View Acumen Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ABOS earnings forecast.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07.

(ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."

Acumen Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.64%), Driehaus Capital Management LLC (1.39%), Pathstone Family Office LLC (1.31%), Silverarc Capital Management LLC (0.73%), Geode Capital Management LLC (0.41%) and WMS Partners LLC (0.24%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F.
View institutional ownership trends.

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABOS stock can currently be purchased for approximately $3.87.

Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $156.74 million and generates $1.44 million in revenue each year.

The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com.